Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljae191 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Lesley E Rhodes. Beteiligte Einrichtung: Dermatology Centre, School of Biological Sciences, Faculty of Biology Medicine & Health, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Protoporphyria, Erythropoietic, Vitamin D. Die Arbeit nennt 10 Literaturangaben. Gefördert von: National Institute of Health Research, Manchester Biomedical Research Centre.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Centre, School of Biological Sciences, Faculty of Biology Medicine & Health, The University of Manchester, Manchester, UK.
- Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK.
ORCID-Profile: Lesley E Rhodes
Förderung
- National Institute of Health Research
- Manchester Biomedical Research Centre
Zitieren
APA
Rhodes, L. E. (2024). Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae191
Vancouver
Rhodes LE. Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae191
BibTeX
@article{Rhodes2024,
author = {Rhodes, Lesley E},
title = {Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljae191}
}
EUVIMED